KAPA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kairos Pharma Ltd (KAPA) is not a good buy for a beginner investor with a long-term horizon at this time. The stock lacks significant positive catalysts, has weak financial performance, and shows a high probability of negative price movement in the short term. Additionally, there are no strong trading signals or influential endorsements to support a buy decision.
The MACD is positive and expanding, which is a mildly bullish signal. However, the RSI is neutral at 63.729, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 0.59, with resistance at 0.619 and support at 0.56. Overall, the technical indicators do not suggest a strong buy opportunity.
NULL identified. No recent news, no significant hedge fund or insider activity, and no recent congressional trading data.
The stock has a 70% chance of declining by -2.35% in the next day, -4.76% in the next week, and -13.24% in the next month. Financial performance remains weak, with no revenue and a negative net income of -1,365,000 in Q4 2025.
In Q4 2025, revenue remained at 0 with no growth. Net income improved slightly YoY but is still negative at -1,365,000. EPS remains at -0.07. Gross margin is 0, indicating no profitability.
No analyst rating or price target data available.
